Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

4059 - Extended adjuvant temozolamide as prognostic factor of longer overall and progression-free survival in glioblastoma multiforme


09 Oct 2016


Poster display


Sara Póvoa


Annals of Oncology (2016) 27 (6): 103-113. 10.1093/annonc/mdw367


S.C. Póvoa1, N. Tavares1, M.J. Ribeiro1, D. Azevedo1, A. Coelho1, A. Fernandes1, A. Costa1, C. Caeiro1, B. Carvalho2, P. Linhares2, L. Osório3, L. Castro4, J. Fonseca5, M. Damasceno1

Author affiliations

  • 1 Medical Oncology Department, Hospital de S. João, 4200–319 - Porto/PT
  • 2 Neurosurgical Department, Hospital de S. João, 4200–319 - Porto/PT
  • 3 Radiation Oncology Department, Hospital de S. João, 4200–319 - Porto/PT
  • 4 Pathology Department, Hospital de S. João, 4200–319 - Porto/PT
  • 5 Neuroradiology Department, Hospital de S. João, 4200–319 - Porto/PT


Abstract 4059


Glioblastoma multiforme (GBM), the most common malignant primary central nervous system tumour, has significant morbi-mortality. The aim is to determine prognostic factors (PF) of overall survival (OS) and progression-free survival (PFS) in patients treated with Stupp protocol.


Retrospective analysis of GBM patients ≥18 years, diagnosed from March 2004 to December 2014, treated with radiotherapy (RT) plus concomitant and adjuvant temozolomide (aTMZ). OS and PFS were assessed by Kaplan-Meier method and multivariate analysis (MA) was performed using Cox regression.


A total of 213 patients completed concomitant TMZ-RT and were included in final analysis. Majority were males (n = 134), with median age of 61 years old (24-84) and 43.1% ECOG performance status 0. Gross total resection (GTR) was possible in 46.9%, partial resection in 33.3% and stereotactic biopsy (SB) in 19.7%. 197 patients proceeded to aTMZ: 107 suspended


Our results suggest an OS and PFS benefit of extended aTMZ beyond standard 6 cycles, with stronger impact in OS with >12 cycles. The retrospective study design limits conclusions and further validation is necessary in prospective randomized studies.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings